ReviewClinical and translational radiation oncology2018
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.
Review in Clinical and translational radiation oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 365 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vaginal Dilatators and Moisturizers Use and Sexual Quality of Life of Patients With Gynecologic Cancer Treated With Brachytherapy.
Integration of Multi-modality Imaging Protocols With emphAsis on CT in Image Guided Adaptive Brachytherapy (IGABT) for Cervical Cancer - EMBRACE III-IMPACT STUDY
Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
Who cites it
365 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Dose-response relationship between volume base dose and tumor local control in definitive radiotherapy for vaginal cancer.BMC cancer · 2024Pooled it
- Clinical application of MR-Linac in tumor radiotherapy: a systematic review.Radiation oncology (London, England) · 2023Pooled it
- Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergoing pelvic radiotherapy for gynecologic cancers: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: A phase II, randomized study.Acta oncologica (Stockholm, Sweden) · 2025Trial
- Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer.Biomolecules & biomedicine · 2023Trial
- Trial
- Cone beam computed tomography guided online adaptive radiotherapy for cervical Cancer: Two-year single-Centre implementation and clinical experience.Technical innovations & patient support in radiation oncology · 2026Article
- Dosimetric evaluation of systematic source position uncertainty along the source path and robust planning during MRI-only cervical HDR brachytherapy.Journal of applied clinical medical physics · 2026Article
- Review
- Treatment Pathways and Candidate Correlates of Surgical Intervention in Locally Advanced Cervical and Other Gynecological Cancers: A Hypothesis-Generating Single-Center Cohort Study.Journal of clinical medicine · 2026Article
- Article
- Applicator-dependent differences between TG-43 and a grid-based Boltzmann solver in iridium-192 high-dose-rate gynecological brachytherapy.Journal of contemporary brachytherapy · 2026Article
- Dosimetric impact of intrarectal gas removal by Foley catheter on image-guided adaptive brachytherapy in cervical cancer patients.Journal of contemporary brachytherapy · 2026Article
- Outcomes of node-positive cervical cancer treated with neoadjuvant chemotherapy followed by radical surgery: a single-center approach to a challenging disease.Journal of gynecologic oncology · 2026Observational
- Impact of qualitative Diffusion weighted imaging and apparent diffusion coefficient (DWI/ADC) on target volume delineation in cervical cancer: a feasibility study.Technical innovations & patient support in radiation oncology · 2026Article
- Can stereotactic body radiotherapy replace brachytherapy in gynecologic cancers? A systematic review of current evidence.Clinical and translational radiation oncology · 2026Review
- The impact of uterine position during brachytherapy on treatment outcomes and toxicity in patients with cervical cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Validation of IBS-GEC ESTRO-ABS Computed Tomography-Based Contouring Recommendations Using Prebrachytherapy Magnetic Resonance Imaging in Patients With Cervical Cancer Treated With Definitive Radiation Therapy.Advances in radiation oncology · 2026Article
- Article
- Mid-treatment MRI-based tumor volume reduction rate as a continuous prognostic factor after chemoradiation for cervical cancer: development and two-center internal-external validation.Journal of radiation research · 2026Article
305 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
The publication of the GEC-ESTRO recommendations one decade ago was a significant step forward for reaching international consensus on adaptive target definition and dose reporting in image guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer. Since then, IGABT has been spreading, particularly in Europe, North America and Asia, and the guidelines have proved their broad acceptance and applicability in clinical practice. However, a unified approach to volume contouring and reporting does not imply a unified administration of treatment, and currently both external beam radiotherapy (EBRT) and IGABT are delivered using a large variety of techniques and prescription/fractionation schedules. With IGABT, local control is excellent in limited and well-responding tumours. The major challenges are currently loco-regional control in advanced tumours, treatment-related morbidity, and distant metastatic disease. Emerging evidence from the RetroEMBRACE and EMBRACE I studies has demonstrated that clinical outcome is related to dose prescription and technique. The next logical step is to demonstrate excellent clinical outcome with the most advanced EBRT and brachytherapy techniques based on an evidence-based prospective dose and volume prescription protocol. The EMBRACE II study is an interventional and observational multicentre study which aims to benchmark a high level of local, nodal and systemic control while limiting morbidity, using state of the art treatment including an advanced target volume selection and contouring protocol for EBRT and brachytherapy, a multi-parametric brachytherapy dose prescription protocol (clinical validation of dose constraints), and use of advanced EBRT (IMRT and IGRT) and brachytherapy (IC/IS) techniques (clinical validation). The study also incorporates translational research including imaging and tissue biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.